United States-based Xeris Pharmaceuticals has started dosing patients in a phase two trial with its ready-to-use, room-temperature stable liquid glucagon in patients with Type one diabetes who experience episodes of exercise-induced hypoglycaemia, it was reported on Friday.
This Phase two study will assess Xeris' ready-to-use glucagon as a pre-treatment to prevent exercise-induced hypoglycaemia in 48 patients with Type one diabetes who receive daily insulin treatment through a subcutaneous infusion pump. In the two-period cross-over comparison study, patients will receive ready-to-use glucagon or placebo at least 45 minutes before moderate or high intensity aerobic exercise in a clinical research centre. Additional data will then be collected through a parallel comparison in an outpatient setting with a similar regimen involving at least 30 minutes of aerobic exercise performed by subjects 3-5 times per week for 12 weeks.
Xeris Pharmaceuticals expects top-line results from the study in the second half of 2019.
vTv Therapeutics secures USD51m private placement for cadisegliatin Phase 3 study
AbbVie names new chief executive officer
SkinBioTherapeutics expands foot care products in AMEA with Dermatonics partnership
Diamyd Medical granted US FDA Fast Track designation for Diamyd diabetes treatment
Insulet's Omnipod 5 integration with Abbott FreeStyle Libre 2 Plus Sensor secures CE Mark approval
Kyowa Kirin enrols first subject in phase two tivozanib eye drops (KHK4951) clinical trial
China accepts GSK's Shingrix application for at-risk adults
Novo Nordisk to boost manufacturing capacity with acquisition of three fill-finish sites
Breye Therapeutics commences phase 1b/2a danegaptide clinical trial
DexCom Inc breaks ground on new manufacturing facility in Ireland
VibroSense Dynamics AB secures provisional patent for chemotherapy-induced nerve damage prediction
Innovent Biologics signs collaboration agreement with Sanegene Bio USA
Japan approves GSK's filing for Arexvy vaccination for at-risk adults